Extended Adjuvant Endocrine Therapy in Breast Cancer: Current Status and Future Directions
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference44 articles.
1. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group;Mouridsen;J Clin Oncol,2003
2. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer [published erratum appears in: N Engl J Med 2006; 354:2200];Thurlimann;N Engl J Med,2005
3. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial [published erratum appears in: Lancet 2007; 369:906];Coombes;Lancet,2007
4. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer;Goss;N Engl J Med,2003
5. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17;Goss;J Natl Cancer Inst,2005
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Young Patients with Hormone Receptor-Positive Breast Cancer Have a Higher Long-Term Risk of Breast Cancer Specific Death;Journal of Breast Cancer;2019
2. Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers;Geburtshilfe und Frauenheilkunde;2018-03
3. Cyclophosphamide causes osteoporosis in C57BL/6 male mice: suppressive effects of cyclophosphamide on osteoblastogenesis and osteoclastogenesis;Oncotarget;2017-09-18
4. Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study;Geburtshilfe und Frauenheilkunde;2014-12-23
5. Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer;Clinical Cancer Research;2014-02-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3